APTAMATRIX - Key Persons

Job Titles:

• Secretary of the Board of Directors

Job Titles:

• CSO
• Member of the Board of Directors
• Member of the Management Team

As the Chief Science Officer, Caitlin's efforts are squarely focused on development and optimization of our current aptamer discovery protocols, leveraging next generation DNA sequencing technology. She was the primary contributor to prior SBIR projects awarded to AptaMatrix that successfully advanced to Phase II. Her experience with aptamer discovery and next generation DNA sequencing is critical for advancing the development of AptaMatrix's mAIA™ methods. She also leads all personnel and aspects of AP3-assay development. Caitlin received her doctorate in Chemistry from Syracuse University (SU) in the laboratory of Dr. Philip Borer. Her dissertation work focused on improving the reliability of aptamer discovery using next generation DNA sequencing and advancing novel partitioning methods for AIA. Following SU, Caitlin joined AptaMatrix as a Senior Scientist where she continued to advance AptaMatrix's aptamer discovery methods in a commercial capacity. She also had a four year appointment as a Visiting Assistant Professor of Chemistry at Le Moyne College.

Job Titles:

• CMO
• Member of the Board of Directors
• Member of the Management Team
• in 2020 As the Chief Medical Officer

Gennady joined AptaMatrix in 2020 as the Chief Medical Officer. As a physician-scientist with experience in both laboratory and clinical research, and practicing urologic oncologist, Gennady is uniquely positioned to contribute to the advancement of the AP3-assay for clinical use. His expertise in basic science, biobanking, FDA processes and regulations, clinical trials, as well as commercializing medical technology, makes him a critical part of the team. He is tasked with supporting the clinical applications of the AP3-assay for detection of prostate cancer using liquid biopsies, and facilitating the transition of the AP3 - assay kits to the clinic for pre-clinical testing. After having served as a Senior Surgeon at the National Cancer Institute (NCI), he became Professor and Chair of the Department of Urology at SUNY Upstate Medical University (Syracuse, NY) in 2011. Gennady also serves as the Director of Prostate Cancer Program, Deputy Director of the Upstate Cancer Center, and Director of the Upstate Biobank. On a national level, after serving as a voting member of the Board of Directors and Renal Organ Site Committee Society of Urologic Oncology-Clinical Trials Consortium (SUO-CTC) in December of 2018 he was elected as a President of the SUO-CTC (the consortium consists of over 200 sites in US and Canada). He has also served as a voting Member of the Board of the Directors of the Northeastern American Urologic Society and GU Steering Committee of the NCI/NIH. Since 2010, he has served on the FDA as a consultant for GI and GU products. In 2015, he successfully launched a medical company, Respiquest, Inc., that produces the respiratory adaptor "MUNODA", presently distributed by Conmed throughout the United States. ​He received his M.D. degree (concentration in Urology) with Distinction in Research from Albany Medical College. He has co-authored more than 130 peer-reviewed publications (both in clinical medicine and laboratory), numerous book chapters and editorials, and has served as a PI or co-PI on numerous clinical trials at the NCI and SUNY Upstate Medical University.

Job Titles:

• CEO
• Chairman of the Board
• Member of the Management Team

As Chief Executive Offer, Mark spearheads the company's research and development efforts. A principal author of SBIR & STTR efforts, he is also the Principal Investigator on a several recently awarded SBIR grant from NIH and Homeland Security Advanced Research Projects Agency (HSARPA). Mark joined AptaMatrix (formerly OrthoSystems) in 2003 with a strong commitment to develop rapid and sensitive detectors for chemical and biological agents under the AlloSwitch project (formerly OrthoSwitch project). This sensor program was directed toward environmental and terrorist threats to public health. Mark's efforts are currently focused on commercializing the AIA™ (formerly HTSA) and mAIA aptamer discovery platform; which is a critical area for company growth. The mAIA™ approach represents the key aptamer discovery method for development of our AP3-assay kit that will find applications in disease discovery using existing next-gen DNA sequencers. ​He received his Ph.D. in Chemistry from Syracuse University in 2001. Prior to joining the company, Mark was an American Foundation for AIDS Research Fellow at the Dana-Farber Cancer Institute at Harvard Medical School, focused on screening small molecules for anti-viral activity.

Job Titles:

• Member of the Board of Directors

Job Titles:

• Member of the Management Team
• Director of Bioinformatics

Vladimir joined AptaMatrix in 2020. As the Director of Bioinformatics he leads all aspects of sequence data processing and the development of custom, internal bioinformatic tools. He has a broad background in computational biomedical sciences and bioinformatics, with deep training and knowledge in integrative biomedical data analysis, method and database development, cancer biology and predictive oncology. His leadership and expertise will be critical for developing the plasma proteome disease profile database that will be leveraged by the AP3-assay platform. Vladimir also has an appointment as Professor in the Urology and Biochemistry & Molecular Biology departments at SUNY Upstate Medical University (Syracuse, NY). From Oct 2007 - Feb 2018, he served as a Senior PI and Head of the Genome and Gene Expression Data Analysis Division at the Bioinformatics Institute (BII), A*STAR (Agency for Science, Technology and Research, Singapore - Singapore government organization with innovative rank 8 among government research organization worldwide in 2016). At the same time, he was also Deputy Director of Graduate Affairs at BII/A-STAR, and an adjunct Professor at Nanyang Technological University (NTU)'s School of Computer Science and Engineering Sciences, and part-time lecturer and consultant at NTU's Nanyang Institute of Technology in Health & Medicine, Singapore. He has authored more than 130 peer reviewed published research articles and reviews, and 2 books. In 1994, He was awarded the P.L. Kapitsa Silver Medal "To the Author of a Scientific Discovery" and elected as a Corresponding Member of the Russian Academy of Natural Sciences.